We provide you with 20 years of free, institutional-grade data for AIKI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AIKI. Explore the full financial landscape of AIKI stock.
| Reported Date | CIK | Ticker | Type |
|---|
AIkido Pharma Inc(NASDAQ:AIKI) 
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC...
Website: http://www.aikidopharma.com
Full Time Employees: 4 (May 2021)
CEO: Anthony C. Hayes
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about AIKI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.